Related Experiment Video
Updated: Apr 1, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
A renaissance in targeting the PI3K/AKT/mTOR pathway
Sarah E Conduit1, Neil Vasan2, Jennifer R Brown3
1UCL Cancer Institute, University College London, London, UK. s.conduit@ucl.ac.uk.
None:
The PI3K/AKT/mTOR pathway represents an excellent drug target, given its proven druggability and roles in cancer, immune regulation and genetic disorders. However, although some agents targeting this pathway have gained approval, drug development has faced challenges due to tolerability issues and resistance mechanisms, amongst other obstacles. New pharmacological approaches and improved biological and clinical understanding are now renewing interest and confidence in therapeutically modulating PI3K/AKT/mTOR signalling. This Perspective covers the challenges, lessons learned and new efforts in targeting this pathway.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

